These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30579959)

  • 1. Aclarubicin in subtoxic doses reduces doxorubicin cytotoxicity in human non-small cell lung adenocarcinoma (A549) and human hepatocellular carcinoma (HepG2) cells by decreasing DNA damage.
    Gajek A; Rogalska A; Koceva-Chyła A
    Toxicol In Vitro; 2019 Mar; 55():140-150. PubMed ID: 30579959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aclarubicin-induced ROS generation and collapse of mitochondrial membrane potential in human cancer cell lines.
    Rogalska A; Koceva-Chyła A; Jóźwiak Z
    Chem Biol Interact; 2008 Oct; 176(1):58-70. PubMed ID: 18692031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in Transport Characteristics and Cytotoxicity of Epirubicin and Doxorubicin in HepG2 and A549 Cells.
    Nagai K; Fukuno S; Shiota M; Tamura M; Yabumoto S; Konishi H
    Anticancer Res; 2021 Dec; 41(12):6105-6112. PubMed ID: 34848465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines.
    Lee TK; Lau TC; Ng IO
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):78-86. PubMed ID: 11855756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours.
    Rogalska A; Szwed M; Jóźwiak Z
    Mutat Res; 2010 Jul; 700(1-2):1-10. PubMed ID: 20399885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The connection between the toxicity of anthracyclines and their ability to modulate the P-glycoprotein-mediated transport in A549, HepG2, and MCF-7 cells.
    Rogalska A; Szwed M; Rychlik B
    ScientificWorldJournal; 2014; 2014():819548. PubMed ID: 24574923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structurally different anthracyclines provoke different effects on cell cycle and tumor B cell differentiation.
    Teillaud JL; Gruel N; Moncuit J; Mishal Z; Fridman WH; Lampidis TJ; Tapiero H
    Biomed Pharmacother; 1998; 52(6):282-90. PubMed ID: 9755828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.
    Lehne G; De Angelis P; Clausen OP; Rugstad HE
    Br J Cancer; 1996 Dec; 74(11):1719-29. PubMed ID: 8956784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I.
    Bridewell DJ; Finlay GJ; Baguley BC
    Oncol Res; 1997; 9(10):535-42. PubMed ID: 9507531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
    Tapiero H; Nguyen-Ba G; Lampidis TJ
    Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
    Jensen PB; Sørensen BS; Demant EJ; Sehested M; Jensen PS; Vindeløv L; Hansen HH
    Cancer Res; 1990 Jun; 50(11):3311-6. PubMed ID: 2159380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells.
    Ling YH; el-Naggar AK; Priebe W; Perez-Soler R
    Mol Pharmacol; 1996 May; 49(5):832-41. PubMed ID: 8622633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation.
    Koceva-Chyła A; Jedrzejczak M; Skierski J; Kania K; Jóźwiak Z
    Apoptosis; 2005 Dec; 10(6):1497-514. PubMed ID: 16215684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced cytotoxicity in doxorubicin-exposed HepG2 cells pretreated with menthol due to upregulation of P-glycoprotein.
    Nagai K; Fukuno S; Miura T; Uchino Y; Sehara N; Konishi H
    Pharmazie; 2020 Oct; 75(10):510-511. PubMed ID: 33305727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of pro-apoptotic activity of doxorubicin-transferrin conjugate in cells derived from human solid tumors.
    Szwed M; Kania KD; Jozwiak Z
    Int J Biochem Cell Biol; 2016 Jan; 70():57-67. PubMed ID: 26520467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro sensitivity of myeloblast clonogenic cells to doxorubicin, aclacinomycin A, and 4'-O-tetrapyranyl-doxorubicin: correlations with clinical responses.
    Georgoulias V; Iskandar YL; Amesland F; Ribaud P; Mathé G; Jasmin C
    J Clin Oncol; 1984 Nov; 2(11):1215-22. PubMed ID: 6593437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotoxic effect of doxorubicin-transferrin conjugate on human leukemia cells.
    Szwed M; Jozwiak Z
    Mutat Res Genet Toxicol Environ Mutagen; 2014 Sep; 771():53-63. PubMed ID: 25308442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gingerol Synergizes the Cytotoxic Effects of Doxorubicin against Liver Cancer Cells and Protects from Its Vascular Toxicity.
    Al-Abbasi FA; Alghamdi EA; Baghdadi MA; Alamoudi AJ; El-Halawany AM; El-Bassossy HM; Aseeri AH; Al-Abd AM
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27399668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of doxorubicin-incorporated magnetic albumin nanospheres.
    Zeybek A; Şanlı-Mohamed G; Ak G; Yılmaz H; Şanlıer ŞH
    Chem Biol Drug Des; 2014 Jul; 84(1):108-15. PubMed ID: 24524300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity and induction of apoptosis by formamidinodoxorubicins in comparison to doxorubicin in human ovarian adenocarcinoma cells.
    Marczak A; Denel-Bobrowska M; Rogalska A; Łukawska M; Oszczapowicz I
    Environ Toxicol Pharmacol; 2015 Jan; 39(1):369-83. PubMed ID: 25561091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.